Biblio
Export 1467 results:
Author [ Title] Type Year Filters: First Letter Of Last Name is K [Clear All Filters]
“Tau Proteins Cross the Blood-Brain Barrier.”, J Alzheimers Dis, vol. 55, no. 1, pp. 411-419, 2017.
, “Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers.”, J Alzheimers Dis, vol. 63, no. 1, pp. 13-33, 2018.
, “Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study.”, J Alzheimers Dis, vol. 55, no. 2, pp. 585-595, 2017.
, “Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study.”, J Alzheimers Dis, vol. 55, no. 2, pp. 585-595, 2017.
, “TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1227-1233, 2018.
, “TDP-43 Pathology in the Setting of Intermediate and High Alzheimer's Disease Neuropathologic Changes: A Preliminary Evaluation Across Ethnoracial Groups.”, J Alzheimers Dis, vol. 91, no. 4, pp. 1291-1301, 2023.
, “Telomere Shortening in the Alzheimer's Disease Neuroimaging Initiative Cohort.”, J Alzheimers Dis, vol. 71, no. 1, pp. 33-43, 2019.
, “Temporal Order of Alzheimer's Disease-Related Cognitive Marker Changes in BLSA and WRAP Longitudinal Studies.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1335-1347, 2017.
, “Ten Challenges of the Amyloid Hypothesis of Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 447-457, 2017.
, “Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults.”, J Am Geriatr Soc, vol. 62, no. 1, pp. 16-24, 2014.
, “Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults.”, J Am Geriatr Soc, vol. 62, no. 1, pp. 16-24, 2014.
, “TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice.”, J Alzheimers Dis, vol. 56, no. 1, pp. 335-349, 2017.
, “TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice.”, J Alzheimers Dis, vol. 56, no. 1, pp. 335-349, 2017.
, “Therapeutics of Neurotransmitters in Alzheimer's Disease.”, J Alzheimers Dis, vol. 57, no. 4, pp. 1049-1069, 2017.
, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
, “Three-Repeat Tau with Grain-Like Structures and Distribution in an 83-Year-Old Man.”, J Alzheimers Dis, vol. 58, no. 3, pp. 681-685, 2017.
, “Three-Repeat Tau with Grain-Like Structures and Distribution in an 83-Year-Old Man.”, J Alzheimers Dis, vol. 58, no. 3, pp. 681-685, 2017.
, “Time Trends in the Prevalence of Neurocognitive Disorders and Cognitive Impairment in the United States: The Effects of Disease Severity and Improved Ascertainment.”, J Alzheimers Dis, vol. 64, no. 1, pp. 137-148, 2018.
, “Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 80, no. 4, pp. 1629-1642, 2021.
, “Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 80, no. 4, pp. 1629-1642, 2021.
, “Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 80, no. 4, pp. 1629-1642, 2021.
, “Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.”, J Alzheimers Dis, vol. 95, no. 1, pp. 213-225, 2023.
,